Literature DB >> 17400690

Pulmonary impairment after tuberculosis.

Jotam G Pasipanodya1, Thaddeus L Miller, Mauricio Vecino, Guadalupe Munguia, Robert Garmon, Sejong Bae, Gerry Drewyer, Stephen E Weis.   

Abstract

BACKGROUND: Pulmonary impairment subsequent to a cure of pulmonary tuberculosis has been described only in selected populations.
METHODS: We compared pulmonary function in a case-control study of 107 prospectively identified patients with pulmonary tuberculosis who had completed at least 20 weeks of therapy and 210 patients with latent tuberculosis infection (LTBI).
RESULTS: Both groups had similar risk factors for pulmonary impairment. Impairment was present in 59% of tuberculosis subjects and 20% of LTBI control subjects. FVC, FEV1, FEV1/FVC ratio, and the midexpiratory phase of forced expiratory flow were significantly lower in the treated pulmonary tuberculosis patients than in the comparison group. Ten patients with a history of pulmonary tuberculosis (9.4%) had less than half of their expected vital capacity vs one patient (0.53%) in the LTBI group. Another 42 patients (39%) with tuberculosis had between 20% and 50% of the expected vital capacity vs 36 patients with LTBI (17%). After adjusting for risk, survivors of tuberculosis were 5.4 times more likely to have abnormal pulmonary function test results than were LTBI patients (p > 0.001; 95% confidence interval, 2.98 to 9.68). Birth in the United States (odds ratio [OR], 2.64; p = 0.003) and age (OR, 1.03; p = 0.005) increased the odds of impairment. Pulmonary impairment was more common in cigarette smokers; however, after adjusting for demographic and other risk factors, the difference did not reach statistical significance (p = 0.074).
CONCLUSIONS: These findings indicate that pulmonary impairment after tuberculosis is associated with disability worldwide and support more aggressive case prevention strategies and posttreatment evaluation. For many persons with tuberculosis, a microbiological cure is the beginning not the end of their illness.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17400690     DOI: 10.1378/chest.06-2949

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  101 in total

Review 1.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

2.  Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology.

Authors:  Selvakumar Subbian; Liana Tsenova; Paul O'Brien; Guibin Yang; Mi-Sun Koo; Blas Peixoto; Dorothy Fallows; Jerome B Zeldis; George Muller; Gilla Kaplan
Journal:  Am J Pathol       Date:  2011-05-07       Impact factor: 4.307

3.  Clinico-Radiologic and Spirometric Profile of an Indian Population with Post-Tuberculous Obstructive Airway Disease.

Authors:  Avradip Santra; Pravati Dutta; Rekha Manjhi; Sudarsan Pothal
Journal:  J Clin Diagn Res       Date:  2017-03-01

4.  Area-level socioeconomic disadvantage and severe pulmonary tuberculosis: U.S., 2000-2008.

Authors:  Eyal Oren; Masahiro Narita; Charles Nolan; Jonathan Mayer
Journal:  Public Health Rep       Date:  2013 Mar-Apr       Impact factor: 2.792

5.  New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.

Authors:  Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

6.  Exertional dyspnea-related acidotic and sympathetic responses in patients with sequelae of pulmonary tuberculosis.

Authors:  Keisuke Miki; Ryoji Maekura; Toru Hiraga; Hisako Hashimoto; Seigo Kitada; Mari Miki; Kenji Yoshimura; Yoshitaka Tateishi; Teppei Sugano; Masaharu Motone
Journal:  J Physiol Sci       Date:  2010-01-20       Impact factor: 2.781

Review 7.  Convergence of non-communicable diseases and tuberculosis: a two-way street?

Authors:  M J Magee; A D Salindri; U P Gujral; S C Auld; J Bao; J S Haw; H-H Lin; H Kornfeld
Journal:  Int J Tuberc Lung Dis       Date:  2018-11-01       Impact factor: 2.373

8.  Mycobacterium Tuberculosis Infection, Immigration Status, and Diagnostic Discordance: A Comparison of Tuberculin Skin Test and QuantiFERON-TB Gold In-Tube Test Among Immigrants to the U.S.

Authors:  Fernando A Wilson; Thaddeus L Miller; Jim P Stimpson
Journal:  Public Health Rep       Date:  2016 Mar-Apr       Impact factor: 2.792

9.  Increased mortality associated with treated active tuberculosis in HIV-infected adults in Tanzania.

Authors:  Conrad Kabali; Lillian Mtei; Daniel R Brooks; Richard Waddell; Muhammad Bakari; Mecky Matee; Robert D Arbeit; Kisali Pallangyo; C Fordham von Reyn; C Robert Horsburgh
Journal:  Tuberculosis (Edinb)       Date:  2013-03-22       Impact factor: 3.131

10.  Pulmonary impairment after tuberculosis and its contribution to TB burden.

Authors:  Jotam G Pasipanodya; Scott Jn McNabb; Peter Hilsenrath; Sejong Bae; Kristine Lykens; Edgar Vecino; Guadalupe Munguia; Thaddeus L Miller; Gerry Drewyer; Stephen E Weis
Journal:  BMC Public Health       Date:  2010-05-19       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.